Trials / Terminated
TerminatedNCT01086761
Study of MP0112 Intravitreal Injection in Patients With Wet Age Related Macular Degeneration
A Phase I/II, Open-label, Non-controlled, Escalating Dose, Multicentre Clinical Trial Evaluating the Safety, Preliminary Efficacy, and Pharmacokinetics of MP0112 Injected Intravitreally in Patients With Wet Age Related Macular Degeneration (AMD)
- Status
- Terminated
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 32 (actual)
- Sponsor
- Allergan · Industry
- Sex
- All
- Age
- 50 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to assess the safety and tolerability of MP0112 (a novel, potentially long acting VEGF inhibitor) in patients with wet Age Related Macular Degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | MP0112 | Single intravitreal injection of MP0112 in the study eye. |
Timeline
- Start date
- 2010-03-01
- Primary completion
- 2010-11-01
- Completion
- 2010-11-01
- First posted
- 2010-03-15
- Last updated
- 2014-05-12
- Results posted
- 2014-05-12
Locations
8 sites across 3 countries: Czechia, France, Switzerland
Source: ClinicalTrials.gov record NCT01086761. Inclusion in this directory is not an endorsement.